Anaprox-DS Pregnancy

• Pregnancy of Anaprox-DS in details
• Anaprox-DS breastfeeding
• Anaprox-DS reviews

Pregnancy of Anaprox-DS in details

Anaprox-DS crosses the placenta (Brogden 1975). Birth defects have been observed following in utero NSAID exposure in some studies; however, data is conflicting (Bloor 2013). Nonteratogenic effects, including prenatal constriction of the ductus arteriosus, persistent pulmonary hypertension of the newborn, oligohydramnios, necrotizing enterocolitis, renal dysfunction or failure, and intracranial hemorrhage have been observed in the fetus/neonate following in utero NSAID exposure. In addition, nonclosure of the ductus arteriosus postnatally may occur and be resistant to medical management (Bermas 2014; Bloor 2013). Because NSAIDs may cause premature closure of the ductus arteriosus, product labeling for Anaprox-DS specifically states use should be avoided starting at 30-weeks gestation. Use of NSAIDs can be considered for the treatment of mild rheumatoid arthritis flares in pregnant women; however, use should be minimized or avoided early and late in pregnancy (Bermas 2014; Saavedra Salinas 2015).

The use of NSAIDs close to conception may be associated with an increased risk of miscarriage (Bloor 2013; Bermas 2014).

Anaprox-DS breastfeeding

Use should be avoided. Excreted into human milk: Yes Comments: The effects in the nursing infant are unknown.

This drug has been found in the milk of lactating women at concentrations of approximately 1% of that found in plasma. Due to the long half-life and potential for serious adverse events in breastfed infants, other agents may be preferred.

See references

References for pregnancy information

1. "Product Information. Anaprox (Anaprox-DS)." Roche Laboratories, Nutley, NJ.
2. MHRA. Medicines and Health Regulatory Agency "MHRA Drug Safety Update. Available from: URL: http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate."
3. "Product Information. Naprosyn (Anaprox-DS)." Syntex Laboratories Inc, Palo Alto, CA.
4. Cerner Multum, Inc. "Australian Product Information." O 0
5. "Product Information. Naprelan 375 (Anaprox-DS)." Shionogi USA Inc, Florham Park, NJ.
6. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0

References for breastfeeding information

1. Cerner Multum, Inc. "Australian Product Information." O 0
2. "Product Information. Naprelan 375 (Anaprox-DS)." Shionogi USA Inc, Florham Park, NJ.
3. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
4. "Product Information. Naprosyn (Anaprox-DS)." Syntex Laboratories Inc, Palo Alto, CA.
5. "Product Information. Anaprox (Anaprox-DS)." Roche Laboratories, Nutley, NJ.
6. MHRA. Medicines and Health Regulatory Agency "MHRA Drug Safety Update. Available from: URL: http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate."
7. United States National Library of Medicine "Toxnet. Toxicology Data Network. Available from: URL: http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT." ([cited 2013 -]):

References

1. DailyMed. "NAPROXEN: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
2. PubMed Health. "Naproxen (By mouth): This section provide the link out information of drugs collectetd in PubMed Health. ". http://www.ncbi.nlm.nih.gov/pubmedhe... (accessed September 17, 2018).
3. Human Metabolome Database (HMDB). "Naproxen: The Human Metabolome Database (HMDB) is a freely available electronic database containing detailed information about small molecule metabolites found in the human body.". http://www.hmdb.ca/metabolites/HMDB0... (accessed September 17, 2018).

Reviews

Consumer reviews

There are no reviews yet. Be the first to write one!

Your name:  Email:  Spam protection:  < Type 24 here

Information checked by Dr. Sachin Kumar, MD Pharmacology